flecainide has been researched along with Cardiovascular Stroke in 77 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide." | 9.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 9.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| "Although active treatment in CAST-I was associated with greater mortality than placebo with respect to almost all baseline variables, the therapeutic hazard was more than expected in patients with non-Q-wave myocardial infarction and (for total mortality) frequent premature VPDs and higher heart rates, suggesting that the adverse effect of encainide or flecainide therapy is greater when ischemic and electrical instability are present." | 9.07 | Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). ( Anderson, JL; Buckingham, TA; Carlson, MD; Carson, PE; Hallstrom, A; Henthorn, RW; Platia, EV, 1994) |
| "A prospective study evaluated the comparative haemodynamic effects of three Class I antiarrhythmics (lignocaine Class 1B, disopyramide Class 1A and flecainide Class 1C) in 30 patients with uncomplicated acute myocardial infarction." | 9.06 | Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Kalra, PA; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1986) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 9.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "We evaluated the hemodynamic effects of the class I antiarrhythmic flecainide in 20 patients within 18 hours of an acute myocardial infarction." | 9.05 | Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation. ( Frais, MA; Hafizullah, M; Jackson, N; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 9.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 7.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "Electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, were examined and compared with those of flecainide, a class Ic antiarrhythmic drug, in a canine myocardial infarction model." | 7.69 | Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. ( Araki, S; Hashimoto, H; Ishii, M; Nagashima, S; Nakashima, M; Uematsu, T; Umemura, K, 1994) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 7.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| "The effect of flecainide in 24 patients with inducible sustained ventricular arrhythmia and a history of remote myocardial infarction was determined." | 7.67 | Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia. ( Greenspan, AM; Horowitz, LN; Morganroth, J; Senior, S; Spielman, SR; Webb, CR, 1986) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 7.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| "Plasma flecainide concentrations were measured in 10 patients with acute myocardial infarction." | 7.67 | Plasma flecainide concentrations following acute myocardial infarction. ( Bhamra, R; Holt, DW; Jackson, G; Johnston, A; Ong, ML, 1987) |
| "During a one-week short-term in-hospital period, 60 patients with chronic ventricular arrhythmias were treated with 200 mg flecainide twice a day." | 7.67 | Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias. ( Balakumaran, K; Hagemeijer, F; Hugenholtz, PG; Jovanovic, A; Lubsen, J; Polak, BC; Roelandt, J; ten Cate, FJ; Vanhaleweyk, G; Withagen, A, 1984) |
| "Hemodynamic and ECG effects of intravenous flecainide were assessed in 10 patients with acute myocardial infarction and no symptoms or signs of heart failure." | 7.67 | Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. ( Cohen, AA; Covelli, G; Daru, V; Gonzalez, M; Tronge, JE; Villamayor, R, 1985) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 7.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 6.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "Phase-2 ventricular arrhythmias occur during infarct evolution." | 5.33 | Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. ( Clements-Jewery, H; Curtis, MJ; Kabra, R; Kanaganayagam, GS, 2006) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 5.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "In this study we investigated the time to the first arrhythmic, ischemic, or failure event for encainide-flecainide and moricizine versus their respective placebo comparison groups in the Cardiac Arrhythmia Suppression Trial." | 5.08 | Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial. ( Anderson, JL; Carlson, M; Davies, R; Duff, HJ; Greene, HL; Hallstrom, AP; Huther, M; Kammerling, JM; Romhilt, DW, 1995) |
| "Encainide, flecainide and moricizine all caused a decrease in RR variability in patients studied approximately 1 month after acute myocardial infarction." | 5.07 | Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. ( Bigger, JT; Fleiss, JL; Rolnitzky, LM; Steinman, RC, 1994) |
| "This report examines whether in the Cardiac Arrhythmia Suppression Trial death and cardiac arrest from encainide, flecainide and moricizine during the titration phase and from encainide and flecainide during the follow-up phase were related to presence (Q-wave acute myocardial infarction [Q-AMI]) or absence (non-Q-AMI) of pathologic Q waves." | 5.07 | Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. ( Akiyama, T; Greenberg, H; Kuo, CS; Pawitan, Y; Reynolds-Haertle, RA, 1991) |
| "Although active treatment in CAST-I was associated with greater mortality than placebo with respect to almost all baseline variables, the therapeutic hazard was more than expected in patients with non-Q-wave myocardial infarction and (for total mortality) frequent premature VPDs and higher heart rates, suggesting that the adverse effect of encainide or flecainide therapy is greater when ischemic and electrical instability are present." | 5.07 | Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). ( Anderson, JL; Buckingham, TA; Carlson, MD; Carson, PE; Hallstrom, A; Henthorn, RW; Platia, EV, 1994) |
| "There was an excess of deaths due to arrhythmia and deaths due to shock after acute recurrent myocardial infarction in patients treated with encainide or flecainide." | 5.07 | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. ( Arensberg, D; Baker, A; Barker, AH; Echt, DS; Friedman, L; Greene, HL; Liebson, PR; Mitchell, LB; Obias-Manno, D; Peters, RW, 1991) |
| "Patients randomized to placebo in the encainide and flecainide arms of the Cardiac Arrhythmia Suppression Trial (CAST) have been found to have a relatively low 1-year mortality rate of 3." | 5.07 | Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. ( Capone, RJ; el-Sherif, N; Geraci, TS; Handshaw, K; Morganroth, J; Pawitan, Y; Schlant, RC; Waldo, AL, 1991) |
| "A prospective study evaluated the comparative haemodynamic effects of three Class I antiarrhythmics (lignocaine Class 1B, disopyramide Class 1A and flecainide Class 1C) in 30 patients with uncomplicated acute myocardial infarction." | 5.06 | Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction. ( Frais, MA; Hafizullah, M; Jackson, NC; Kalra, PA; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP, 1986) |
| " The Cardiac Arrhythmia Suppression Trial (CAST) is evaluating the effect of antiarrhythmic therapy (encainide, flecainide, or moricizine) in patients with asymptomatic or mildly symptomatic ventricular arrhythmia (six or more ventricular premature beats per hour) after myocardial infarction." | 5.06 | Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. ( , 1989) |
| "In 12 patients with coronary artery disease, 11 of them with previous myocardial infarction, the antiarrhythmic effects of orally administered flecainide (F." | 5.05 | [Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)]. ( Fabry, E; Klempt, HW; Nayebagha, A, 1982) |
| "We evaluated the hemodynamic effects of the class I antiarrhythmic flecainide in 20 patients within 18 hours of an acute myocardial infarction." | 5.05 | Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation. ( Frais, MA; Hafizullah, M; Jackson, N; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1985) |
| "A variety of recent in vivo studies have sought to clarify the mechanism underlying the proarrhythmic response of flecainide in the Cardiac Arrhythmia Suppression Trial (CAST)." | 4.79 | Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding. ( Cragun, KT; Johnson, SB; Munger, TM; Packer, DL, 1997) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was designed to test the hypothesis that suppression of ventricular premature complexes (VPCs) in survivors of acute myocardial infarction would reduce arrhythmic death risk." | 3.76 | The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. ( Moye, LA; Pratt, CM, 1990) |
| "The Cardiac Arrhythmia Suppression Trial has shown that flecainide was associated with an increased incidence of sudden cardiac death in postinfarction patients." | 3.69 | Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. ( Assadi, MA; Avitable, MJ; Caref, EB; el-Sherif, N; Isber, N; Ndrepepa, G; Patel, AI; Restivo, M; Yin, H, 1995) |
| "The class IC antiarrhythmic drug flecainide has been shown to be ineffective for the treatment of ventricular arrhythmias in some patients who have had a prior myocardial infarction and sometimes even provoke arrhythmias (proarrhythmic effect)." | 3.69 | Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. ( Coromilas, J; Dillon, SM; Saltman, AE; Waldecker, B; Wit, AL, 1995) |
| "Electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, were examined and compared with those of flecainide, a class Ic antiarrhythmic drug, in a canine myocardial infarction model." | 3.69 | Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model. ( Araki, S; Hashimoto, H; Ishii, M; Nagashima, S; Nakashima, M; Uematsu, T; Umemura, K, 1994) |
| "In order to study the effects of treatment with class 1 antiarrhythmics on the metabolic, hemodynamic, and electrocardiographic responses to adrenaline, 12 healthy volunteers were infused on four occasions, after pretreatment with placebo, disopyramide, mexiletine, and flecainide, respectively, with adrenaline at a rate producing serum adrenaline concentrations comparable with those seen in acute myocardial infarction." | 3.68 | Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics. ( Gullberg, B; Hansen, O; Johansson, BW, 1991) |
| "Effects of flecainide, a class I antiarrhythmic drug, on ventricular arrhythmias, ventricular abnormal automaticity and ventricular activation were examined in a canine model of myocardial infarction, and compared with those of lidocaine." | 3.68 | Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction. ( Hashimoto, H; Katoh, H; Nakashima, M, 1992) |
| "The antiarrhythmic and antifibrillatory actions of the class IC antiarrhythmic agent flecainide acetate were examined in urethane-anesthetized dogs with recent myocardial infarction." | 3.67 | Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. ( DiCarlo, LA; Lucchesi, BR; Lynch, JJ; Montgomery, DG, 1987) |
| "The haemodynamic effects of flecainide were compared in three different subsets of patients with documented coronary disease." | 3.67 | Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. ( Collignon, P; Kulbertus, HE; Legrand, V; Materne, P; Vandormael, M, 1985) |
| "During a one-week short-term in-hospital period, 60 patients with chronic ventricular arrhythmias were treated with 200 mg flecainide twice a day." | 3.67 | Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias. ( Balakumaran, K; Hagemeijer, F; Hugenholtz, PG; Jovanovic, A; Lubsen, J; Polak, BC; Roelandt, J; ten Cate, FJ; Vanhaleweyk, G; Withagen, A, 1984) |
| "Hemodynamic and ECG effects of intravenous flecainide were assessed in 10 patients with acute myocardial infarction and no symptoms or signs of heart failure." | 3.67 | Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. ( Cohen, AA; Covelli, G; Daru, V; Gonzalez, M; Tronge, JE; Villamayor, R, 1985) |
| "Plasma flecainide (FLC) levels versus time were measured in a group of 10 acute myocardial infarction (AMI) patients at our Intensive Care Unit." | 3.67 | Clinical pharmacokinetics of intravenous flecainide in critically ill patients. ( Ibáñez, P; Rodriguez, M; Sánchez-Alcaraz, A; Sangrador, G, 1989) |
| "Flecainide has been reported to be effective in suppressing chronic ventricular arrhythmias in clinical studies, but the electrophysiological mechanisms of its action are not understood." | 3.67 | Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model. ( Hosokawa, M; Miyazaki, T; Nakamura, Y; Ogawa, S; Sakai, T; Sakurai, K, 1989) |
| "Plasma flecainide concentrations were measured in 10 patients with acute myocardial infarction." | 3.67 | Plasma flecainide concentrations following acute myocardial infarction. ( Bhamra, R; Holt, DW; Jackson, G; Johnston, A; Ong, ML, 1987) |
| "The effect of flecainide in 24 patients with inducible sustained ventricular arrhythmia and a history of remote myocardial infarction was determined." | 3.67 | Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia. ( Greenspan, AM; Horowitz, LN; Morganroth, J; Senior, S; Spielman, SR; Webb, CR, 1986) |
| " 2,5-Bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide acetate (flecainide, R 818, Tambocor) caused a significant increase of the atrial and ventricular fibrillation thresholds." | 3.66 | Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs. ( Bender, F; Gülker, H; Heuer, H; Thale, J, 1983) |
| "Sudden cardiac death was observed in 16 patients, 8 patients in each group." | 2.72 | Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study. ( Crijns, HJ; Hagens, VE; Rienstra, M; Van Gelder, IC; Van Veldhuisen, DJ, 2006) |
| "Baseline data from the Cardiac Arrhythmia Suppression Trial were used to define several categories of heart failure and to relate both the resulting categories and ejection fraction to arrhythmia suppression and mortality using logistic and survival regression analytic methodologies." | 2.68 | Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. ( DeMaria, A; Gottlieb, S; Greene, HL; Hallstrom, A; Huther, M; Pratt, CM; Young, JB, 1995) |
| " Adverse events including death are more frequent in older patients taking study drugs (P less than 0." | 2.67 | Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. ( Akiyama, T; Barker, AH; Campbell, WB; Friedman, L; Josephson, RA; Keller, M; Papa, L; Pawitan, Y; Rubbert, P, 1992) |
| "Patients whose arrhythmias were suppressed were randomized in the main study and those whose arrhythmias were partially suppressed were randomized in a substudy." | 2.67 | Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. ( Bigger, JT; Epstein, AE; Hallstrom, AP; Reynolds-Haertle, RA; Romhilt, DW; Wyse, DG, 1991) |
| "The Cardiac Arrhythmia Suppression Trial-1, a pharmacologic test of the arrhythmia suppression and mortality hypothesis among postmyocardial infarction patients, allowed a prospective test of the relationship of distress, perceived support, social interaction, life stress, and other variables, to mortality, adjusting statistically for ejection fraction, arrhythmia rates, and other known risk factors for coronary heart disease." | 2.67 | Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). ( Brooks, MM; Gorkin, L; Kellen, J; Morris, M; Pawitan, Y; Schoenberger, JA; Schron, EB; Shumaker, S; Verter, J; Wiklund, I, 1993) |
| "The Cardiac Arrhythmia Suppression Trial (CAST) was a study designed to test the hypothesis that suppression of ventricular premature complexes after a myocardial infarction would improve survival." | 2.67 | The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. ( Greene, HL; Henthorn, RW; Katz, RJ; Roden, DM; Salerno, DM; Woosley, RL, 1992) |
| " During a double-blind drug and dose selection phase, investigators were permitted to change drug or dosage to achieve greater than or equal to 70% suppression in VPC frequency and greater than 90% suppression of runs of VPC with the exception of patients assigned to placebo, who continued receiving it." | 2.66 | Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. ( , 1988) |
| "Amiodarone has been demonstrated to be more efficacious than propafenone or sotalol in the Canadian Trial of Atrial Fibrillation." | 2.42 | Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. ( Bhatta, L; Hynes, J; Khan, M; Luck, J; Naccarelli, GV; Samii, S; Wolbrette, DL, 2003) |
| "Current management of ventricular arrhythmias are considered in the light of these findings." | 2.38 | Treatment of ventricular arrhythmias after CAST. ( Tonkin, AM, 1992) |
| "Control animals developed premature ventricular complexes (PVCs) followed by ventricular tachycardia, which terminated in VF in 5 of the 8 dogs." | 1.39 | HBI-3000 prevents secondary sudden cardiac death. ( Lee, JY; Lucchesi, BR, 2013) |
| "Phase-2 ventricular arrhythmias occur during infarct evolution." | 1.33 | Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts. ( Clements-Jewery, H; Curtis, MJ; Kabra, R; Kanaganayagam, GS, 2006) |
| "flecainide were examined in rats with postischemic left ventricular dysfunction." | 1.28 | [Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function]. ( Beyer, M; Hoffmeister, HM; Hörmann, HP; Seipel, L, 1990) |
| "An example from the Cardiac Arrhythmia Suppression Trial (CAST) illustrates what we term the 'healthy responder' phenomenon." | 1.28 | The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators. ( Greene, HL; Hallstrom, AP; Huther, ML, 1991) |
| "Flecainide (F) is a new antiarrhythmic agent recently introduced into clinical practice." | 1.28 | [Kinetics of intravenously administered flecainide in patients with acute myocardial infarct]. ( Carelli, M; Di Marcotullio, G; Giampaolo, P; Malinconico, U; Milazzotto, F; Polizzi, CA; Tubaro, M, 1989) |
| " Seven additional postinfarction dogs with noninducible tachycardia during pretreatment programmed stimulation, and thereby considered to be at "low risk" for the development of ischemic ventricular fibrillation, were also given flecainide in an intravenous loading and maintenance dosing regimen." | 1.27 | Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. ( DiCarlo, L; Kou, WH; Lucchesi, BR; Lynch, JJ; Montgomery, DG; Nelson, SD, 1987) |
| "Disopyramide was only modestly active, while flecainide and encainide had the least favorable profiles of effect in suppressing re-entry arrhythmias in this model." | 1.27 | Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model. ( Gomoll, AW, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (49.35) | 18.7374 |
| 1990's | 32 (41.56) | 18.2507 |
| 2000's | 6 (7.79) | 29.6817 |
| 2010's | 1 (1.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Johnson, RE | 1 |
| Baizman, ER | 1 |
| Becker, C | 1 |
| Bohnet, EA | 1 |
| Bell, RH | 1 |
| Birsner, NC | 1 |
| Busacca, CA | 1 |
| Carabateas, PM | 1 |
| Chadwick, CC | 1 |
| Gruett, MD | 1 |
| Lee, JY | 1 |
| Lucchesi, BR | 3 |
| Naccarelli, GV | 1 |
| Wolbrette, DL | 1 |
| Khan, M | 1 |
| Bhatta, L | 1 |
| Hynes, J | 1 |
| Samii, S | 1 |
| Luck, J | 1 |
| Dun, W | 1 |
| Baba, S | 1 |
| Yagi, T | 1 |
| Boyden, PA | 2 |
| Fukuda, K | 1 |
| Davies, SS | 1 |
| Nakajima, T | 1 |
| Ong, BH | 1 |
| Kupershmidt, S | 1 |
| Fessel, J | 1 |
| Amarnath, V | 1 |
| Anderson, ME | 1 |
| Viswanathan, PC | 1 |
| Roberts, LJ | 1 |
| Balser, JR | 1 |
| Clements-Jewery, H | 1 |
| Kanaganayagam, GS | 1 |
| Kabra, R | 1 |
| Curtis, MJ | 1 |
| Hagens, VE | 1 |
| Rienstra, M | 1 |
| Van Veldhuisen, DJ | 1 |
| Crijns, HJ | 1 |
| Van Gelder, IC | 1 |
| Klempt, HW | 1 |
| Nayebagha, A | 1 |
| Fabry, E | 1 |
| Heuer, H | 4 |
| Gülker, H | 4 |
| Thale, J | 4 |
| Bender, F | 4 |
| Hellestrand, KJ | 1 |
| Vanhaleweyk, G | 1 |
| Balakumaran, K | 1 |
| Lubsen, J | 1 |
| ten Cate, FJ | 1 |
| Jovanovic, A | 1 |
| Hagemeijer, F | 1 |
| Withagen, A | 1 |
| Polak, BC | 1 |
| Roelandt, J | 1 |
| Hugenholtz, PG | 1 |
| Brisse, B | 1 |
| Kristek, J | 2 |
| Schindelhauer, F | 2 |
| Teerling, K | 1 |
| Hübner, G | 1 |
| Bigger, JT | 2 |
| Rolnitzky, LM | 1 |
| Steinman, RC | 1 |
| Fleiss, JL | 1 |
| Hallstrom, AP | 6 |
| Anderson, JL | 4 |
| Carlson, M | 1 |
| Davies, R | 1 |
| Greene, HL | 6 |
| Kammerling, JM | 1 |
| Romhilt, DW | 2 |
| Duff, HJ | 1 |
| Huther, M | 2 |
| Ranger, S | 1 |
| Nattel, S | 1 |
| Kidwell, GA | 1 |
| Gonzalez, MD | 1 |
| Coromilas, J | 1 |
| Saltman, AE | 1 |
| Waldecker, B | 1 |
| Dillon, SM | 1 |
| Wit, AL | 1 |
| Hallstrom, A | 3 |
| Pratt, CM | 2 |
| Gottlieb, S | 1 |
| DeMaria, A | 1 |
| Young, JB | 2 |
| Restivo, M | 1 |
| Yin, H | 1 |
| Caref, EB | 1 |
| Patel, AI | 1 |
| Ndrepepa, G | 1 |
| Avitable, MJ | 1 |
| Assadi, MA | 1 |
| Isber, N | 1 |
| el-Sherif, N | 2 |
| Platia, EV | 1 |
| Henthorn, RW | 2 |
| Buckingham, TA | 1 |
| Carlson, MD | 1 |
| Carson, PE | 1 |
| Hashimoto, H | 2 |
| Umemura, K | 1 |
| Araki, S | 1 |
| Ishii, M | 1 |
| Nagashima, S | 1 |
| Uematsu, T | 1 |
| Nakashima, M | 2 |
| Epstein, AE | 2 |
| Rogers, WJ | 1 |
| Liebson, PR | 2 |
| Seals, AA | 1 |
| Cohen, JD | 2 |
| Capone, RJ | 3 |
| Wyse, DG | 3 |
| Ogawa, S | 2 |
| Mitamura, H | 1 |
| Katoh, H | 2 |
| Gorkin, L | 1 |
| Schron, EB | 1 |
| Brooks, MM | 1 |
| Wiklund, I | 1 |
| Kellen, J | 1 |
| Verter, J | 1 |
| Schoenberger, JA | 1 |
| Pawitan, Y | 4 |
| Morris, M | 1 |
| Shumaker, S | 1 |
| Greenberg, HM | 1 |
| Dwyer, EM | 1 |
| Hochman, JS | 1 |
| Steinberg, JS | 2 |
| Echt, DS | 3 |
| Peters, RW | 2 |
| Kellen, JC | 1 |
| Ettinger, A | 1 |
| Todd, L | 1 |
| Brezsnyak, ML | 1 |
| Campion, J | 1 |
| McBride, R | 3 |
| Thomas, S | 1 |
| Corum, J | 1 |
| Schron, E | 1 |
| Packer, DL | 1 |
| Munger, TM | 1 |
| Johnson, SB | 1 |
| Cragun, KT | 1 |
| Tonkin, AM | 1 |
| Winslow, E | 1 |
| Mason, R | 1 |
| Roden, DM | 2 |
| Katz, RJ | 1 |
| Woosley, RL | 1 |
| Salerno, DM | 1 |
| Akiyama, T | 2 |
| Campbell, WB | 1 |
| Papa, L | 1 |
| Barker, AH | 4 |
| Rubbert, P | 1 |
| Friedman, L | 2 |
| Keller, M | 1 |
| Josephson, RA | 1 |
| Greenberg, H | 1 |
| Kuo, CS | 1 |
| Reynolds-Haertle, RA | 2 |
| Kerin, NZ | 1 |
| Hansen, O | 1 |
| Johansson, BW | 1 |
| Gullberg, B | 1 |
| Mitchell, LB | 1 |
| Obias-Manno, D | 1 |
| Arensberg, D | 1 |
| Baker, A | 1 |
| Mahmarian, J | 1 |
| Geraci, TS | 1 |
| Handshaw, K | 1 |
| Morganroth, J | 2 |
| Schlant, RC | 1 |
| Waldo, AL | 1 |
| Huther, ML | 1 |
| Moye, LA | 1 |
| Furlanello, F | 1 |
| Hoffmeister, HM | 1 |
| Hörmann, HP | 1 |
| Beyer, M | 1 |
| Seipel, L | 1 |
| Richardson, DW | 1 |
| Griffith, LS | 1 |
| Ledingham, RB | 1 |
| Reiffel, JA | 1 |
| Yusuf, S | 1 |
| Fowles, RE | 1 |
| Polizzi, CA | 1 |
| Carelli, M | 1 |
| Giampaolo, P | 1 |
| Di Marcotullio, G | 1 |
| Tubaro, M | 1 |
| Malinconico, U | 1 |
| Milazzotto, F | 1 |
| Farré, J | 1 |
| Brugada, P | 1 |
| Coyle, JD | 1 |
| Schaal, SF | 1 |
| Ruskin, JN | 1 |
| Sangrador, G | 1 |
| Sánchez-Alcaraz, A | 1 |
| Rodriguez, M | 1 |
| Ibáñez, P | 1 |
| Garratt, C | 2 |
| Ward, DE | 1 |
| Camm, AJ | 3 |
| Sakai, T | 1 |
| Hosokawa, M | 1 |
| Miyazaki, T | 1 |
| Sakurai, K | 1 |
| Nakamura, Y | 1 |
| Gallicchio, F | 1 |
| Aragona, PL | 1 |
| Chiatto, M | 1 |
| Pugliese, F | 1 |
| Donnangelo, L | 1 |
| Ward, D | 1 |
| Szatmáry, LJ | 1 |
| Bernadet, P | 1 |
| Puel, P | 1 |
| Mikloweit, P | 1 |
| Bienmüller, H | 1 |
| Kou, WH | 1 |
| Nelson, SD | 1 |
| Lynch, JJ | 2 |
| Montgomery, DG | 2 |
| DiCarlo, L | 1 |
| Silke, B | 2 |
| Frais, MA | 2 |
| Verma, SP | 2 |
| Reynolds, GW | 1 |
| Hafizullah, M | 2 |
| Kalra, PA | 1 |
| Jackson, NC | 1 |
| Taylor, SH | 2 |
| Ong, ML | 1 |
| Jackson, G | 1 |
| Johnston, A | 2 |
| Bhamra, R | 1 |
| Holt, DW | 1 |
| DiCarlo, LA | 1 |
| Gomoll, AW | 1 |
| Goedel-Meinen, L | 1 |
| Hofmann, M | 1 |
| Schmidt, G | 1 |
| Barthel, P | 1 |
| Baedeker, W | 1 |
| Blömer, H | 1 |
| Zha, YM | 1 |
| Cha, YM | 1 |
| Zhang, AP | 1 |
| Liu, L | 1 |
| Sun, JP | 1 |
| Huang, W | 1 |
| Webb, CR | 1 |
| Senior, S | 1 |
| Spielman, SR | 1 |
| Greenspan, AM | 1 |
| Horowitz, LN | 1 |
| Jackson, N | 1 |
| Reynolds, G | 1 |
| Caplin, JL | 1 |
| Hamer, J | 1 |
| Kinnaird, AA | 1 |
| Lederman, CL | 1 |
| Man, RY | 1 |
| Legrand, V | 1 |
| Materne, P | 1 |
| Vandormael, M | 1 |
| Collignon, P | 1 |
| Kulbertus, HE | 1 |
| Cohen, AA | 1 |
| Daru, V | 1 |
| Covelli, G | 1 |
| Gonzalez, M | 1 |
| Villamayor, R | 1 |
| Tronge, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Ability of Several Short-term Measures of RR Variability to Predict Mortality After Myocardial Infarction[NCT00005235] | 715 participants (Actual) | Observational | 1988-12-31 | Completed | |||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| [NCT00000504] | Phase 2 | 0 participants | Interventional | 1982-09-30 | Completed | ||
| Can Global Peak Longitudinal Strain Measurements in Combination With Non-invasive ECG Parameters Predict the Success or Failure of Flecainide Treatment for Atrial Fibrillation Patients?[NCT05084495] | 100 participants (Anticipated) | Observational | 2022-02-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
6 reviews available for flecainide and Cardiovascular Stroke
| Article | Year |
|---|---|
Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Australia; Canada; Controlled Clinical Tria | 2003 |
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Mechanism of lethal proarrhythmia observed in the Cardiac Arrhythmia Suppression Trial: role of adrenergic modulation of drug binding.
Topics: Animals; Arrhythmias, Cardiac; Flecainide; Heart Conduction System; Humans; Myocardial Infarction | 1997 |
Treatment of ventricular arrhythmias after CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic | 1992 |
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Myocardial In | 1990 |
[Postinfarct ventricular extrasystole and the use of anti-arrhythmic drugs: a danger anticipated by electrophysiologists].
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Death, Sudden; Electrophysiology; Flecainide; | 1989 |
30 trials available for flecainide and Cardiovascular Stroke
| Article | Year |
|---|---|
Determinants of sudden cardiac death in patients with persistent atrial fibrillation in the rate control versus electrical cardioversion (RACE) study.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Calcium | 2006 |
[Antiarrhythmic efficacy of mexiletine, propafenone and flecainide in ventricular premature beats. A comparative study in patients after myocardial infarction (author's transl)].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Coronary Disease; Electrocardiogr | 1982 |
Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy.
Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography, Ambulatory; Encainide; Fe | 1994 |
Time to arrhythmic, ischemic, and heart failure events: exploratory analyses to elucidate mechanisms of adverse drug effects in the Cardiac Arrhythmia Suppression Trial.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; Heart Fail | 1995 |
Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial.
Topics: Arrhythmias, Cardiac; Electrocardiography; Encainide; Female; Flecainide; Heart Failure; Humans; Mal | 1995 |
Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; Middle Aged; Moricizine; Myocardi | 1994 |
Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; Mid | 1993 |
Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1).
Topics: Arrhythmias, Cardiac; Chi-Square Distribution; Encainide; Flecainide; Humans; Moricizine; Myocardial | 1993 |
Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST I.
Topics: Angina Pectoris; Anti-Arrhythmia Agents; Databases, Factual; Death, Sudden, Cardiac; Drug Interactio | 1995 |
The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
Topics: Aged; Anti-Arrhythmia Agents; Critical Care; Death, Sudden, Cardiac; Encainide; Female; Flecainide; | 1996 |
The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Flecainide; Humans; Mo | 1992 |
Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators.
Topics: Adult; Age Factors; Aged; Aging; Arrhythmias, Cardiac; Drug Therapy, Combination; Encainide; Flecain | 1992 |
Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.
Topics: Cardiac Complexes, Premature; Cause of Death; Drug Combinations; Electrocardiography; Encainide; Fem | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.
Topics: Actuarial Analysis; Anilides; Arrhythmias, Cardiac; Electrocardiography; Encainide; Flecainide; Foll | 1991 |
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Double-Blind Method; Encainide; Female; Flec | 1991 |
Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Female; Flecainide; Humans; Male; | 1991 |
Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chi-Square Distribution; Double-Blind Method; En | 1991 |
The Cardiac Arrhythmia Suppression Trial: background, interim results and implications.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Encainide; Flecainide; Humans; Myocardial In | 1990 |
[Cardiac arrhythmia suppression trial (CAST)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Death, Sudden; Flecainide; H | 1990 |
Recruitment and baseline description of patients in the Cardiac Arrhythmia Pilot Study. The Cardiac Arrhythmia Pilot Study (CAPS) investigators.
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography; Encainide; Feas | 1988 |
Congestive heart failure after acute myocardial infarction in patients receiving antiarrhythmic agents for ventricular premature complexes (Cardiac Arrhythmia Pilot Study).
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Double-Blind Method; Encainide; Fema | 1989 |
Relation of baseline characteristics to suppression of ventricular arrhythmias during placebo and active antiarrhythmic therapy in patients after myocardial infarction.
Topics: Anilides; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Encainide; Flecainide; Humans; Imipr | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.
Topics: Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical | 1989 |
An interim perspective on the removal of encainide and flecainide from the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Ethics, | 1989 |
Lessons from the cardiac arrhythmia suppression trial.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Encainide; Flecain | 1989 |
Flecainide and CAST.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Encainide; Flecainide; Huma | 1989 |
Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Metho | 1988 |
Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.
Topics: Adult; Aged; Disopyramide; Flecainide; Hemodynamics; Humans; Infusions, Intravenous; Lidocaine; Male | 1986 |
[Effect of class I anti-arrhythmia agents on the signal-averaged ECG].
Topics: Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Clinical Trials as Topic; Coronary Disease; Disopyr | 1988 |
Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Blood Pressure; Clinical Trials as Topic; Dose-Response Relatio | 1985 |
42 other studies available for flecainide and Cardiovascular Stroke
| Article | Year |
|---|---|
4,5-Dihydro-1-phenyl-1H-2,4-benzodiazepines: novel antiarrhythmic agents.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzodiazepines; Cats; Disease Models, Animal | 1993 |
HBI-3000 prevents secondary sudden cardiac death.
Topics: Animals; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Disease Models, Animal; Dogs; Dose-Response | 2013 |
[Caution in therapy of ventricular extrasystole. Staying safe with electrolytes].
Topics: Anti-Arrhythmia Agents; Aspartic Acid; Cardiac Complexes, Premature; Cause of Death; Drug Combinatio | 2002 |
Dynamic remodeling of K+ and Ca2+ currents in cells that survived in the epicardial border zone of canine healed infarcted heart.
Topics: Animals; Calcium Channels; Cell Survival; Dogs; Electric Conductivity; Flecainide; Male; Myocardial | 2004 |
Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels.
Topics: Aldehydes; Arrhythmias, Cardiac; Cell Line; Flecainide; Humans; Isoprostanes; Lipid Peroxidation; My | 2005 |
Actions of flecainide on susceptibility to phase-2 ventricular arrhythmias during infarct evolution in rat isolated perfused hearts.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Susceptibility; Drug Design; Flecaini | 2006 |
Effects of flecainide on atrial and ventricular stimulation thresholds to repetitive extrasystoles and fibrillation and on "2nd Phase" ventricular arrhythmias in dogs.
Topics: Animals; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Dogs; Electric Stimulation; Female; F | 1983 |
Flecainide: one-year efficacy in patients with chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Dizziness; Drug Evaluation; Electrocardiography; | 1984 |
[Anti-arrhythmia and antifibrillatory effect of flecainide in programmed ventricle stimulation and in recent heart infarction].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Ventricles; Myocardia | 1982 |
[Antiarrhythmic therapy with flecainide in acute experimental myocardial infarction (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Heart Rate; Hemodynamics; Myocardial Infarction; Ox | 1981 |
[Anti-arrhythmia effect of flecainide in acute myocardial infarct in comparison with lidocaine].
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Dogs; Flecainide; Lidocaine; Myocardial Infarction; Pi | 1981 |
Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs.
Topics: Animals; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Fl | 1995 |
Effects of flecainide and D-sotalol on myocardial conduction and refractoriness: relation to antiarrhythmic and proarrhythmic drug effects.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electric Stimulation; Electrocardiography; Electrophysiology; F | 1993 |
Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts.
Topics: Animals; Anisotropy; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Dogs; Electrocardiography; El | 1995 |
Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Dogs; Electrocard | 1995 |
Comparison of electrophysiologic and hemodynamic effects of SD-3212, a new antiarrhythmic drug, and flecainide in a canine myocardial infarction model.
Topics: Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac Output; Disease Models, Animal; Dogs; Dose- | 1994 |
Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disease Models, Animal; Disopyrami | 1993 |
Comparative hemodynamic effects of Org 7797, flecainide, and propafenone in anesthetized pigs with developing myocardial infarcts.
Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Dose-Response Relationship, Drug; Estrenes; Femal | 1992 |
Effects of flecainide on ventricular arrhythmias, abnormal automaticity and activation in a canine model of myocardial infarction.
Topics: Animals; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electrocardiography; Flecainide; Heart | 1992 |
Crime, misdemeanor, and arrhythmia decoding CAST.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Encainide; Flecainide; Heart V | 1991 |
Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics.
Topics: Adult; Analysis of Variance; Blood Pressure; Disopyramide; Electrocardiography; Epinephrine; Flecain | 1991 |
The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Data Interpretation, Statistical; Double-Blind Metho | 1991 |
[Negative inotropic effect of flecainide on the post-ischemic heart with limited contractile function].
Topics: Animals; Blood Pressure; Coronary Disease; Flecainide; Heart Rate; Male; Myocardial Contraction; Myo | 1990 |
[Kinetics of intravenously administered flecainide in patients with acute myocardial infarct].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Flecainide; Heart Ventricle | 1989 |
The cardiac arrhythmia suppression trial (CAST).
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Encainide; Flecainide; Humans | 1989 |
Clinical pharmacokinetics of intravenous flecainide in critically ill patients.
Topics: Acute Disease; Aged; Aged, 80 and over; Female; Flecainide; Half-Life; Humans; Injections, Intraveno | 1989 |
Electrophysiological effects of flecainide in a canine 7 day old myocardial infarction model.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocard | 1989 |
[Short- and medium-term treatment of ventricular hyperkinetic arrhythmia with flecainide].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Flecainide; Follow-Up Studies; Humans; Male | 1989 |
Cardiac arrhythmia suppression trial and flecainide.
Topics: Flecainide; Heart Arrest; Humans; Myocardial Infarction; Product Surveillance, Postmarketing; Tachyc | 1989 |
Mechanical circulatory assistance in the management of patients in coronary care unit.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Angioplasty, Balloon; Cardiac Surgical Procedures; | 1988 |
[Drug-induced intrahepatic cholestasis caused by flecainide acetate and enalapril].
Topics: Aged; Cholestasis, Intrahepatic; Drug Therapy, Combination; Enalapril; Female; Flecainide; Heart Fai | 1987 |
Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death.
Topics: Animals; Death, Sudden; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Electric Stimula | 1987 |
Plasma flecainide concentrations following acute myocardial infarction.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Female; Flecainide; Humans; Male; Middle Aged; Myo | 1987 |
Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction.
Topics: Animals; Blood Pressure; Dogs; Electric Stimulation; Female; Flecainide; Heart Rate; Male; Myocardia | 1987 |
Assessment of drug effects on spontaneous and induced ventricular arrhythmias in a 24-h canine infarction model.
Topics: Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Dogs; Electrocardiogr | 1987 |
[An electrophysiologic study on the anti-ischemic arrhythmia effect of flecainide].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Electrophysiology; Flecainide; Myocardial Infarction | 1988 |
Flecainide acetate in dogs with ischemic tachyarrhythmia. An electrophysiologic study.
Topics: Animals; Dogs; Flecainide; Heart Conduction System; Myocardial Infarction; Tachycardia; Ventricular | 1988 |
Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiography; Female; Flecaini | 1986 |
The acute changes in serum binding of disopyramide and flecainide after myocardial infarction.
Topics: Aged; Anti-Arrhythmia Agents; Blood Proteins; Disopyramide; Female; Flecainide; Humans; Male; Middle | 1985 |
Electrophysiological actions of flecainide in normal and infarcted canine Purkinje fibers.
Topics: Action Potentials; Animals; Dogs; Electrophysiology; Female; Flecainide; Heart Conduction System; In | 1985 |
Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy.
Topics: Adult; Aged; Blood Pressure; Coronary Disease; Electrocardiography; Female; Flecainide; Heart Rate; | 1985 |
Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction.
Topics: Adult; Electrocardiography; Female; Flecainide; Heart Conduction System; Hemodynamics; Humans; Male; | 1985 |